Base editing

Gene therapy
#Base editing #Beam Therapeutics #ESGCT #Lipid based nanoparticle (LNP) #Phase II trial

Initial data from Phase I/II trial of base editing therapy at ESGCT

Beam Therapeutics will present initial data from the ongoing Phase I/II clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa) at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT).   BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation… Read More

#News

#Base editing #Beam Therapeutics #FDA #Gene editing #Gene therapy #Rare disease

FDA clears base editing therapy for phenylketonuria

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for Beam Therapeutics’ BEAM-304 for the treatment of phenylketonuria (PKU).   PKU is a rare, inherited metabolic disorder that results in toxic accumulation of phenylalanine (Phe), leading to serious neurologic and neurocognitive impairments… Read More

#News #Regulatory #Trending News

Gene editing
#Base editing #Beam Therapeutics #Clinical trial #Gene editing #Gene therapy #mRNA

First clinical genetic correction of a disease-causing mutation reported

Biotechnology company Beam Therapeutics says initial data from its Phase I/II trial establish clinical proof-of-concept for BEAM-302 as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.  Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was… Read More

#Editor's Choice #News